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1. Introduction 
1950’s: Clinical reports that transaminases released from dying myocytes could be detected 
via laboratory testing, aiding in the diagnosis of myocardial infarction. The race to define 
clinical markers to aid in the diagnosis, prognosis, and risk stratification of patients with 
potential cardiovascular disease begins. Initial serum markers included AST, LDH, total CK 
and α-hydroxybutyrate. These enzymes are all released in varying amounts by dying 
myocytes. Lack of sensitivity and specificity for cardiac muscle necrosis fuels continued 
research. 
1960’s:CK known to be released during muscle necrosis (including cardiac).Quantitative 
assays were cumbersome and difficult to perform. Total CK designed as a fast, reproducible 
spectrophotometric assay in the late 1960’s.CK isoenzymes are subsequently described: MM, 
MB and BB fractions. 
In 1970’s MB fraction noted to be elevated in and highly specific for acute MI. 
CKMB now measured via a highly sensitive monoclonal antibody assay. It was felt for a 
time that quantitative CKMB determination could be used to enzymatically measure the size 
of an infarct. This has been complicated by release of additional enzymes during 
reperfusion. As CK-MB assays become more sensitive, researchers come to the paradoxical 
realization that it too is not totally cardiac specific. The MB fraction is determined to be 
expressed in skeletal muscle, particularly during the process of muscle regeneration and the 
search for cardiac specificity continues. 
Research turns towards isolation of and development of assays for sarcomeric proteins. 
Myosin light chains were originally isolated and then subsequently abandoned because of 
specificity issues. Troponin I first described as a biomarker specific for AMI in 1987; 
Troponin T in 1989. Now troponins are the biochemical “gold standard” for the diagnosis of 
acute myocardial infarction via consensus of ESC/ACC.  
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Fig. 1. Timeline showing landmark events in the development of cardiac biomarkers 
1.1 Cardiac Markers: What are we looking at? 
A biomarker is defined as a measurable substance or parameter that is an indicator of an 
underlying biological or pathological process. Therefore, depending on the underlying 
process that we are referring to, the cardiac markers can be classified as markers of necrosis, 
markers of ischemia and markers of inflammation. The features of an ideal cardiac marker 
would be: 
 High sensitivity and specificity 
 Rise and fall rapidly after ischemia 
 Able to perform reliably and uniformly 
 Be simple to perform 
 Have turnaround time <60 min 
 Not influenced by functioning of other organs, in particular, functioning of kidney. 
Therefore, cardiac marker is an umbrella term which is used to define present day used 
necrosis markers as well as all the upstream markers of necrosis studied/under study 
including proinflammatory cytokines, cellular adhesion molecules, acute phase reactants, 
plaque destabilization biomarkers, plaque rupture biomarker and prenecrosis ischemia 
biomarkers. This can be simply visualized with the help of following flow diagram: 
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Fig. 2. Flowchart showing significance of biomarkers at various levels in the pathogenesis of 
acute coronary syndrome  
1.2 Markers of cardiac necrosis 
Cardiac markers are used in the diagnosis and risk stratification of patients with chest pain 
and suspected acute coronary syndrome (ACS). The cardiac troponins, in particular, have 
become the cardiac markers of choice for patients with ACS. Indeed, cardiac troponin is 
central to the definition of acute myocardial infarction (MI) in the consensus guidelines from 
the American College of Cardiology (ACC) and the European Society of Cardiology. 
Older Definition of Myocardial Infarction- WHO 1979 
1. Definite acute myocardial infarction-Definite acute myocardial infarction is diagnosed 
in the presence of unequivocal EKG changes and/or unequivocal enzyme changes; the 
history may be typical or atypical. 
2. Possible acute myocardial infarction-Possible acute myocardial infarction is diagnosed 
when serial, equivocal ECG changes persist more than 24 hours, with or without 
equivocal enzyme changes; the history may be typical or atypical. 
3. Old myocardial infarction-Old myocardial infarction is usually diagnosed on an 
unequivocal ECG in the absence of a history or enzymatic signs of acute myocardial 
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infarction. If there are no residual ECG changes, the diagnosis may be based on earlier, 
typical ECGs or on the presence of prior unequivocal serum enzyme changes. 
Redefinition of Myocardial Infarction- Joint Task Force of the European Society of Cardiology, 
American College of Cardiology Foundation, the American Heart Association, and the 
World Health Federation (ESC/ACCF/AHA/WHF) 2007 
A typical rise and/or gradual fall (troponin) or more rapid rise and fall (CK-MB) of 
biochemical markers of myocardial necrosis, with at least one of the following is required: 
 Ischemic symptoms 
 Development of pathologic Q waves on the ECG 
 ECG changes indicative of ischemia (ST segment elevation or depression) 
 Imaging evidence of new loss of viable myocardium or a new regional wall motion 
abnormality. 
In addition, pathologic findings (generally at autopsy) of an acute MI are accepted criteria. 
Markers of cardiac necrosis have come a long way since 1950s. Some of the markers used in 
the past are no longer in use today. Current markers and those used in the past have been 
outlined in the table below. Those used in the past are not discussed separately further. 
 
Current Cardiac Markers 
 CK-MB 
 Myoglobin 
 CKMB Isoforms 
 Troponin I and T 
Cardiac Markers of the Past 
 Total CK Activity 
 Aspartate Aminotransferase Activity 
 Lactate Dehydrogenase Activity 
 LD1/LD2 Ratio 
Table 1. Various present day and past cardiac biomarkers  
2. Creatine kinase  
The enzyme creatinine kinase (formerly referred to as creatinine phosphokinase) exists as 
three isoenzyme forms: CK-MM, CK- MB, and CK-BB. These isoenzymes are found in the 
cytosol and facilitate the egress of high energy phosphates into and out of mitochondria. 
CK: Dimer composed of 2 monomers:  M (43,000 Da) and B  (44,500 Da)---- > CK BB or CK 
MB or CK MM 
Role: Creatine + ATP <---> ADP + Phosphocreatine + Energy (muscular contraction) 
CK BB : Increased in neurological  diseases ; prostatectomy; digestive cancers 
CK MB : Increased with AMI 
CK MM :Increased in myopathy, hypothyroidism, polymyositis,  rhabdomyolysis, muscle 
trauma, intensive exercise, AMI 
Table 2. Isoenzymes of Creatinine Kinase 
Distribution of CK: Creatine Kinase (CK) isoenzyme activity is distributed in a number of 
tissues. The percentage of CK-MB fraction found in the heart is higher than in most other 
tissues. However, sensitive radioimmunoassays are able to detect small amounts of B 
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chain protein in skeletal muscle, and some muscles have been reported to contain up to 10 
percent B chain protein. Most muscles have much more CK per gram than heart tissue .As 
a result, despite containing only a small percent of B chain protein, skeletal muscle 
breakdown can lead to absolute increases in CK-MB in the plasma. Therefore, skeletal 
muscle damage can confound the diagnosis of an MI, as CK-MB can be released. The 
following are examples: 
 Myocardial injury after cardiopulmonary resuscitation 
 Cardioversion 
 Defibrillation 
 Cardiac and non-cardiac surgical procedures 
 Blunt chest trauma with possible cardiac contusion 
 Cocaine abuse  
Total CK, CK-MB and CK-MB to Total CK ratio: Since CK is widely distributed in tissues, 
elevations in total serum CK lack specificity for cardiac damage, which improves with 
measurement of the MB fraction. The normal range of CK also varies considerably; a 
twofold or greater increase in the CK concentration is required for diagnosis. This criterion 
can be problematic in older individuals who, because of their lower muscle mass, may have 
low baseline serum total CK and, during MI, may have elevated serum CK-MB with values 
of total CK that rise but remain within the normal range. For these reasons, total CK has not 
been used in the diagnosis of myocardial damage for years. CK-MB has high specificity for 
cardiac tissue and was the preferred marker of cardiac injury for many years. An elevated 
CK-MB is relatively specific for myocardial injury, particularly in patients with ischemic 
symptoms when skeletal muscle damage is not present. Assays for CK-MB can be 
performed easily and rapidly. Most assays measure CK-MB mass; such measurements are 
more sensitive than activity assays. The relative index calculated by the ratio of CK-MB 
(mass) to total CK can assist in differentiating false-positive elevations of CK-MB arising 
from skeletal muscle. A ratio of less than 3 is consistent with a skeletal muscle source, while 
ratios greater than 5 are indicative of a cardiac source. Ratios between 3 and 5 represent a 
gray zone. No definitive diagnosis can be established without serial determinations to detect 
a rise. Studies to evaluate the CK-MB relative index compared with the absolute CK-MB 
have revealed increase in specificity but with a loss of sensitivity. The CK-MB/CK relative 
index is useful if patients have only an MI or only skeletal muscle injury, but not if they 
have both. In the combined setting of acute MI and skeletal muscle injury (rhabdomyolysis, 
heavy exercise, polymyositis), the fall in sensitivity is significant. It is worth noting that the 
diagnosis of acute MI must not be based on an elevated relative index alone, because the 
relative index may be elevated in clinical settings when either the total CK or the CK-MB is 
within normal limits. The relative index is only clinically useful when both the total CK and 
the CK-MB levels are increased.  
Timing of Release: Creatinine Kinase starts rising in the blood 4-6 hours after the onset of 
chest pain. It peaks at 10-24 hours and then returns to normal after 48-72 hours. Since CK 
levels return to baseline 48 to 72 hours after infarction, it can be used to detect reinfarction. 
New elevations that occur after normalization are indicative of recurrent injury, again with 
the caveats in regard to sensitivity and specificity indicated above. However, for these 
reasons, CK-MB cannot be used for late diagnosis. 
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Fig. 3. Kinetics of CKMB release after AMI 
Sensitivity and Specificity of CKMB: In AMI, CKMB usually is evident at 4 to 8 hours, peaks at 
15 to 24 hours (mean peak=16×normal) with sensitivity and specificity >97% within the first 
48 hours. By 72 hours, two thirds of patients still show some increase in CK-MB. Sampling 
every 6 hours is more likely to identify a peak value. False negative results may be caused 
by poor sample timing (e.g. only once in 24 hours or sampling <4 hours or >72 hours after 
AMI). Similarly, false positive may be caused by a variety of factors including but not 
limited to myocardial injury after cardiopulmonary resuscitation, cardioversion, 
defibrillation, cardiac and non-cardiac surgical procedures, blunt chest trauma with possible 
cardiac contusion and cocaine abuse.  
CK and coronary reperfusion :The time to peak CK levels and the slope of CK-MB release can 
be used to assess whether reperfusion has occurred after fibrinolysis and, when used in 
conjunction with clinical variables, can predict whether TIMI 0 or 1 and TIMI 2 or 3 grade 
flow is present. The 2004 task force of the ACC/AHA concluded that serial measurements of 
CK-MB can be useful to provide supportive noninvasive evidence of reperfusion after 
fibrinolysis (class IIa recommendation). However, it should be noted that CK-MB criteria 
cannot identify the presence of TIMI 3 flow, which is the only level of perfusion associated 
with improved survival after fibrinolysis. Thus, many may elect invasive evaluation despite 
biomarker evidence of reperfusion. The 2004 ACC/AHA task force recommended specific 
guidelines for the diagnosis of reinfarction after an acute ST elevation MI. Within the first 18 
hours of the initial MI, a recurrent elevation in CK-MB concentration alone should not be 
relied upon to diagnose reinfarction, but should be accompanied by recurrent ST segment 
elevation on ECG and at least one other supporting criterion (such as recurrent chest pain or 
hemodynamic decompensation). For patients more than 18 hours from the initial MI, a 
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biomarker rise and at least one additional criterion is sufficient for the diagnosis. Similar 
criteria were established for patients presenting with possible reinfarction after 
percutaneous coronary intervention or coronary artery bypass grafting.  
3. Cardiac Troponins 
Cardiac Troponins (cTn) control the calcium-mediated interaction of actin and myosin. It 
exists in three isoforms: troponin C, troponin I and troponin T. Troponin C exists in all 
muscle tissues. cTnI is however, completely specific for the heart. cTnT released in small 
amounts by skeletal muscles, though clinical assays do not detect skeletal TnT. Both have 
cytosolic or early releasable and structural pools, with most existing in the structural pool. 
They are more specific compared to CKMB in detection of infarction and are the preferred 
biomarker for the diagnosis of acute MI (Class I recommendation from the ACC/AHA task 
force on diagnosis of AMI). 
 
Characteristics Troponin C Troponin I Troponin T 
Weight 18 KD 26.5 KD 39 KD 
Function Calcium binding 
subunit 
Actomyosin-ATP-
inhibiting subunit 
Anchors troponin 
complex to the 
tropomyosin strand 
Cardiac Specificity None Yes Yes 
Table 3. Troponin Characteristics. KD: Kilo Dalton 
3.1 Timing of release 
Cardiac troponins begin rising in the blood 4-6 hours post infarction (same time as CKMB). 
It peaks in 12-24 hours but may take weeks to return to normal. The timing of release, peak 
and normal return as compared to CKMB has been presented in a graphical form below. 
3.2 Sensitivity and specificity of cardiac troponins 
Cardiac troponins are as sensitive as CK-MB during the first 48 hours after acute myocardial 
infarction. The sensitivity is 33% from 0-2 hours, 50% from 2-4 hours, 75% from 4-8 hours 
and approaching 100% from 8 hours after onset of chest pain. The specificity is close to 
100%.  Troponin elevations have been reported in a variety of clinical scenarios other than 
acute coronary syndromes. The following is a list of some of the causes for the elevation of 
troponin in the absence of a thrombotic occlusion of the coronary artery: 
 Tachy- or bradyarrhythmias, or heart block 
 Critically ill patients, especially with diabetes, respiratory failure or sepsis 
 Hypertrophic cardiomyopathy 
 Coronary vasospasm 
 Acute neurological disease, including stroke or subarachnoid hemorrhage 
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 Cardiac contusion or other trauma including surgery, ablation, pacing, implantable 
cardioverter-defibrillator shocks, cardioversion, endomyocardial biopsy, cardiac 
surgery, following interventional closure of atrial septal defects 
 Rhabdomyolysis with cardiac injury 
 Congestive heart failure - acute and chronic 
 Pulmonary embolism, severe pulmonary hypertension 
 Renal failure 
 Aortic dissection 
 Aortic valve disease 
 Apical ballooning syndrome - Takotsubo Cardiomyopathy 
 Infiltrative diseases (ie, amyloidosis, hemochromatosis, sarcoidosis, and scleroderma) 
 Inflammatory diseases (ie, myocarditis or myocardial extension of endo-/pericarditis, 
Kawasaki disease) 
 Drug toxicity or toxins (ie, adriamycin, 5-flurouracil, herceptin, snake venom) 
 Burns, especially if affecting >25 percent of body surface area 
 Extreme exertion 
 Transplant vasculopathy 
The 2007 joint ESC/ACCF/AHA/WHF task force recommends that an elevated value of 
cardiac troponin, in the absence of clinical evidence of ischemia, should prompt a search for 
other causes of myocardial necrosis as listed above. 
3.3 Troponin assays 
The skeletal and cardiac isoforms of troponin T and troponin I are distinct, and skeletal 
isoforms are not detected by the monoclonal antibody-based assays currently in use. This 
specificity for cardiac isoforms is the basis for the clinical utility of cTnT and cTnI assays. 
Contemporary troponin assays are quite sensitive and can detect very small amounts of 
myocardial necrosis (<1 g). Troponin C is not used clinically because both cardiac and 
smooth muscle share troponin C isoforms. The ESC/ACC recommended that the diagnosis 
of MI be based on troponin levels in excess of the 99th percentile of a reference control 
group. As cTnT and cTnI levels are undetectable in most normal subjects, the 99th percentile 
is very low (eg, 0.04 to 0.5 micrograms/L). However, most assays are imprecise at this low 
level, and so it has been recommended that the definition of MI be raised to that value at 
which a specific assay has a coefficient of variation of 10 percent or less. New guidelines 
embrace 99th percentile for two reasons. This level is also low (0.1 to 1.2 micrograms/L), but 
higher than the 99th percentile standard. Due to variations in assay precision and individual 
laboratory policies, the upper limit of normal varies between laboratories, but in all cases is 
above the 99th percentile. 
3.4 Point-of-care assays 
The National Academy of Clinical Biochemistry (NACB) recommendations specify that 
cardiac markers be available on an immediate basis 24 h/d, 7 d/wk, with a turnaround time 
of 1 hour. Point-of-care (POC) devices that provide rapid results should be considered in 
hospitals whose laboratories cannot meet these guidelines. POC assays for CK-MB, 
myoglobin, and the cardiac troponins TnI and TnT are available. Only qualitative TnT 
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assays are available as POC tests, but both quantitative and qualitative POC TnI assays are 
currently marketed. In a multicenter trial, the time to positivity was significantly faster for 
the POC device than for the local laboratory (2.5 h vs 3.4 h).In another multicenter study, 
which evaluated the i-STAT POC TnI assay in comparison with the central laboratory in 
2000 patients with suspected ACS, POC testing reduced the length of stay by approximately 
25 minutes for patients who were discharged from the ED. The sensitivity of current POC 
assays coupled with the benefit of rapid turnaround time make the POC assays attractive 
clinical tools in the ED.  
3.5 Prognostic value of cardiac troponins 
In addition to its use in the diagnosis of MI, an elevated troponin level can identify patients at 
high risk for adverse cardiac events. Specifically, data from a meta-analysis indicated that an 
elevated troponin level in patients without ST-segment elevation is associated with a nearly 4-
fold increase in the cardiac mortality rate. In patients without ST-segment elevation who were 
being considered for thrombolytic therapy, initial TnI levels on admission correlated with 
mortality at 6 weeks, but CK-MB levels were not predictive of adverse cardiac events and had 
no prognostic value. Other studies revealed that an elevated troponin level at baseline was an 
independent predictor of mortality, even in patients with chest pain and acute MI with ST-
segment elevation who were eligible for reperfusion therapy. Finally, the TIMI IIIB, GUSTO 
IIa, GUSTO IV ACS, and FRISC trial all demonstrated a direct correlation between the level of 
TnI or TnT and the mortality rate and adverse cardiac event rate in ACS. 
3.6 High Sensitive Troponin (hsTroponin) 
High-sensitive assay is one which has a total imprecision of less than 10% at the 99th 
percentile and some would propose also being able to quantitate over 50% of normal values 
below that 99th percentile. High-sensitive cTn assays have two differentiating features from 
contemporary cTn assays: 1) detection of cTn in healthy persons and 2) a precise definition 
of what is “normal” (= the 99th percentile). Recent multicenter studies have shown that 
high-sensitive cTn assays improve the early diagnosis of acute myocardial infarction (AMI). 
To achieve the best clinical use, cTn has to be interpreted as a quantitative variable. Rising 
and/or falling levels differentiate acute from chronic cardiomyocyte necrosis. The term 
“troponin-positive” should therefore be avoided. “Detectable” levels will become the norm 
and have to be clearly differentiated from “elevated” levels. The differential diagnosis of a 
small amount of cardiomyocyte necrosis and therefore mild elevation of cTn is broad and 
includes acute and chronic cardiac disorders. The differential diagnosis of a large amount of 
cardiomyocyte necrosis and therefore substantial elevation of cTn is much smaller and 
largely restricted to AMI, myocarditis and Takotsubo cardiomyopathy. Two large 
prospective multicenter studies showed that sensitive and high-sensitive cTn assays have a 
higher diagnostic accuracy compared to contemporary cTn assays at presentation, in the 
diagnosis of AMI.  Earlier “rule in” may reduce morbidity by allowing earlier 
revascularization, earlier transfer to the coronary care unit, and earlier initiation of evidence-
based AMI treatment. Nonetheless, the improvement in sensitivity is at the expense of 
specificity. There is still considerable controversy in regard to how to use these assays to 
detect acute events such as AMI. Hence, at this time it has not been approved for clinical use 
and is yet in research phase. 
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4. Myoglobin 
Myoglobin is a heme protein found in skeletal and cardiac muscle that has attracted 
considerable interest as an early marker of MI. Its low molecular weight accounts for its 
early release profile: myoglobin typically rises 2-4 hours after onset of infarction, peaks at 6-
12 hours, and returns to normal within 24-36 hours. Rapid myoglobin assays are available, 
but overall, they have a lack of cardiospecificity. Serial sampling every 1-2 hours can 
increase the sensitivity and specificity; a rise of 25-40% over 1-2 hours is strongly suggestive 
of acute MI. However, in most studies, myoglobin only achieved 90% sensitivity for acute 
MI, so the negative predictive value of myoglobin is not high enough to exclude the 
diagnosis of acute MI. The original studies that evaluated myoglobin used the WHO 
definition of acute MI that was based on a CK-MB standard. With the adoption of a troponin 
standard for acute MI in the ACC/ESC definition, the sensitivity of myoglobin for acute MI 
is substantially reduced. This significantly diminishes its utility, and a number of studies 
have indicated that contemporary cardiac troponin assays render the use of myoglobin 
measurements unnecessary.  
 
Conditions where myoglobin increases Conditions where myoglobin does 
not increase 
Acute myocardial infarction Non cardiac chest pain 
Vigorous exercise Mild to moderate exercise 
Open heart surgery CHF without acute myocardial 
infarction 
Rhabdomyolysis Cardiac catheterization 
Progressive muscular dystrophy  
Shock  
Renal Failure  
Table 4. Serum myoglobin in various clinical conditions 
4.1 Timing of release, peak and return to baseline of various cardiac markers 
CAD is highly prevalent in patients with CKD, making interpretation of cardiac markers 
important. Despite this, interpretation of elevated cardiac enzymes in patients with renal 
failure is often confusing at best. Elevations in serum troponin often observed in 
asymptomatic patients with chronic kidney disease. Even using the most conservative cutoff 
values, a disproportionate number of patients still have elevated troponins. The mechanism 
for this is unclear. In a 2002 study in Circulation, 733 asymptomatic patients with ESRD were 
evaluated. Using conservative cutoff values, 
- 82% had elevated cTnT  
- 6% had elevated cTnI  
Of those 733 asymptomatic patients on HD, 2-year mortality rates were 52% in those with 
cTnI ≥0.1 µg/dL .These data have been corroborated in a number of smaller studies in 
similar populations. Serial measurements are helpful in the setting of possible ACS. cTnI 
appears to be much less likely to be associated with false positives in the CKD population 
than cTnT, making it the preferred biomarker in this setting. 
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Fig. 4. A comparison of CKMB, cardiac troponins and myoglobin. 
4.2 Markers of inflammation 
Acute coronary syndromes are caused by vulnerable plaques. It is thought that one of the 
driving forces causing atheromatous plaques to rupture or erode, causing a cascade of 
events leading to coronary artery occlusion, is inflammation in the plaques. In this section 
cardiac inflammatory markers are dealt with which is at the verge of entering into clinical 
practice as tool for diagnosing and predicting future cardiovascular events at earlier stage 
and for risk stratification. Highly Sensitive Creative Protein (hsCRP), Myeloperoxidase 
(MPO), Matrix Metalloproteinases (MMP), Pregnancy Associated Protein A(PAPP-
A),Placenta Growth Factor(PIGF) are reviewed. 
4.3 C-Reactive protein (CRP)  
C Reactive Protein is an acute phase reactant synthesized in liver and is elevated in 
inflammatory conditions. Once ligand-bound, CRP can activate the classical compliment 
pathway, stimulate phagocytosis and bind to immunoglobulin receptors. "High-sensitivity" 
only means that the concentration of CRP was determined using an assay designed to 
measure very low levels of CRP. The American Heart Association has defined risk groups as 
follows: Low risk: less than 1.0 mg/L, Average risk: 1.0 to 3.0 mg/L and High risk: above 3.0 
mg/L. Two assays averaged fasting or non fasting, and optimally 2 weeks apart, provide a 
more stable estimate of level of this marker. If a level is greater than 10 mg/L is identified, 
there should be a search initiated for an obvious source of infection or inflammation, which 
could obscure any prediction of coronary risk that might be attributed to the elevated 
level. The landmark study by Liuzzo et al. showed that patients presenting with unstable 
angina and elevated plasma concentrations of CRP had a higher rate of death, MI and need 
for re-vascularisation compared with patients without elevated concentrations.  In more 
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recent trials, other investigators have confirmed the increased risk in ACS associated with 
higher CRP concentrations. In each of the above studies, the predictive value of CRP was 
independent of, and additive to, cardiac troponin. More importantly, CRP was found to 
have prognostic value even among patients with negative cardiac troponin and no evidence 
of myocyte necrosis. Methodological issues have however been highlighted and the 
independence between CRP and troponin release questioned. Therefore , although many 
studies have suggested that low-grade hsCRP elevations are independently associated with 
coronary risk, more complete evidence is needed to validate the use of hs-CRP as a risk 
assessment tool in general practice and as a target for therapy in individual patients . 
4.4 Myeloperoxidase (MPO) 
Myeloperoxidase (MPO) is a hemoprotein that is abundantly expressed in 
polymorphonuclear cells (neutrophils) and secreted during their activation. The presence of 
a peroxidase in the cytoplasmic granules of leukocytes was suggested at the beginning of 
20th century but it was the early 1940s that it was purified for the first time. MPO plays an 
important role in neutrophil microbicidal action through catalyzing chloride ion oxidation 
to hypochlorous acid, which is a potent antimicrobial agent. On the other hand, it was 
demonstrated that MPO causes oxidative modification of low density lipoprotein (LDL) to a 
high uptake form that is considered to be a key event in the promotion of atherogenesis. 
Hence myeloperoxidase is believed to participate in the initiation and progression of 
cardiovascular diseases. MPO possesses potent proinflammatory properties and may 
contribute directly to tissue injury. 
In a study consisted of patients diagnosed with ACS and other heart disease or 
unspecified chest pain, considerably higher MPO concentrations were demonstrated in the 
troponin-negative ACS patients on admission who became troponin-positive after 6h. This 
suggests that level of MPO possessed remarkably higher sensitivity than assessment of cTnI 
alone in all patients with ACS.  MPO levels are associated with the presence of 
angiographically proven coronary atherosclerosis. In addition to clinical history and other 
tools MPO has been approved by FDA as cardiac biomarker to evaluate the patients with 
chest pain and at high risk for coronary artery disease. 
4.5 Matrix metalloproteinases (MMP) 
MMP are endogenous zinc dependent endopeptidases required for structural integrity of 
extracellular matrix of myocardium. TIMP (Tissue Inhibitors of Metalloproteinases) 
regulates MMP. MMPs may degrade myocardial ECM leading to the development of LV 
dilatation and heart failure and their inhibition in experimental models of AMI has been 
associated with reduced LV dilatation and wall stress. In a study of patients with acute 
myocardial infarction, TIMP-1 and MMP-9 correlated with echocardiographic parameters of 
LV dysfunction and remodelling after AMI and identified patients at risk of subsequent LV 
remodeling and associated with severe extensive CAD. 
4.6 Placental Growth Factors (PGF) 
Placental Growth Factor is a member of VEGF (vascular endothelial growth factor) 
subfamily - a key molecule in angiogenesis and vasculogenesis, in particular during the 
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embryogenesis. Placental growth factor expression within human atherosclerotic lesions is 
associated with plaque inflammation and neovascular growth. Recent studies established 
the role of different inflammatory markers such as hsCRP, sr amyloid A, IL-6 not only gets 
elevated during acute coronary syndrome (ACS) but predicts its adverse outcomes. PGF 
was recently shown that it is upregulated in all forms of atherosclerotic lesions. PGIF 
induces the following  
 Vascular smooth muscle cell growth. 
 Recruits macrophages into atherosclerotic lesions. 
 Upregulates production of TNF alpha. 
 Monocyte chemotactic protein 1 by macrophages. 
 Pathological angiogenesis. 
Plasma PIGF levels may be an independent inflammatory biomarker of poor outcome in 
patients with suspected ACS. A single initial measurement of plasma PIGF appears to 
extend the predictive and prognostic information gained from traditional inflammatory 
markers. 
5. Pregnancy associated plasma protein alpha (PAPP-A) 
PAPP-A was originally identified in the serum of pregnant women. PAPP-A is produced by 
placental tissue. Circulating PAPP-A levels increase during pregnancy and they are used in 
the fetal diagnosis of Down syndrome. Only recently has PAPP-A been identified in 
nonplacental tissues. The concentrations in the sera of nonpregnant human beings being 
several orders of magnitude lower than during pregnancy. The physiological role of PAPP-
A is only beginning to be unraveled. PAPP-A is a high-molecular-weight, zinc-binding 
metalloproteinase, which acts as a specific protease of IGF binding protein-4 (IGFBP-
4). There is histological evidence, using specific monoclonal antibodies, that PAPP-A is 
abundantly expressed in both eroded and ruptured coronary plaques, but not in stable 
plaques, in patients who have died suddenly of cardiac causes. Furthermore, accumulating 
evidence suggests that PAPP-A may play a pivotal role in the development of 
atherosclerosis and subsequent plaque instability in ACS patients. PAPP-A is markedly 
elevated in the earliest hours after the onset of symptoms in patients with STEMIs treated 
with heparin and primary percutaneous coronary intervention, and in animal studies, 
heparin administration is associated with a significant increase in PAPP-A levels, 
presumably because of the detachment of PAPP-A from the vessel wall. If future studies 
confirm that concomitant heparin administration also increases PAPP-A levels in humans, 
the prognostic role of PAPP-A in patients with ST elevation myocardial infarction needs to 
be reevaluated.  
5.1 Markers of ischemia 
An ideal marker is one in which there is a specific easily measurable increase that clearly 
aligns with a predictable outcome be it evidence of ischemia, inflammation, myocardial 
necrosis, plaque rupture, plaque destabilization, or heart failure. Because of the underlying 
shared etiologies related to the process of arteriosclerosis and the complexity of the 
pathological processes giving rise to adverse thrombotic outcomes, a single marker that 
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relates to each stage is unlikely. Rather more probable would be use of multiple markers 
with varying decision levels to either rule-in or rule-out a clinical decision. As the 
understanding of the niceties between ACS, inflammation, and coronary artery process 
develops, the ongoing search for better cardiac markers will continue. 
5.2 Ischemia modified albumin (IMA) 
The only ischemia marker that has been approved by the FDA is the modified albumin 
(IMA) using the albumin cobalt binding test (ACB) for assessment of myocardial ischemia. 
IMA occurs in 2 forms: 1.in which human serum albumin (HAS) binds mostly copper and 
2.in which the damage to the N-terminus prevents metal binding. Patients without ischemia 
have more available metal binding sites on their HSA, than those from ischemic patients. 
This alteration is most likely due to damage caused by oxidative free radicals prevalent 
during ischemic events, and resulting in altered binding of trace metals resulting in IMA. As 
mentioned earlier, the FDA approved method for IMA (ACB Test by Ischemia Technologies) 
uses cobalt in its assay. Normal HSA will bind cobalt when it is added to a sample, leaving 
little residual cobalt. However, IMA cannot do the same due to its altered binding site. 
Patients having transient ischemic episodes without parallel myocyte death increases IMA 
which causes less cobalt binding and more residual unbound cobalt available. This can 
complex with chromogen (dithiothreitol) which can be measured photometrically. It is 
estimated that approximately 1% to 2% of the total albumin concentration in the normal 
population is IMA compared to 6% to 8% in patients experiencing ischemia. The clinical 
utility of IMA appears to be in its negative predictive value for ischemia and ACS, 
particularly when used in conjunction with other tests. While the optimum cutoff for IMA 
for ruling out ACS is 85kU/L, the manufacturer has suggested a higher value of 100 kU/L 
for risk stratification. Some of the limitations to be taken into consideration includes: a. there 
is an overlap between the normal population and that of individuals with cardiac ischemia; 
b. IMA is not specific for cardiac ischemia; c. false positive can occur in patients with 
cirrhosis, bacterial and viral infections, advanced cancers, stroke and end-stage renal disease 
and d. interpretation of IMA in certain populations, including those with peripheral 
vascular disease and in marathon runners is not yet clear. Hence IMA appears at this time as 
a potential marker in certain clinical situations but a number of possible interferences may 
limit its utility in patients with suspected ACS. 
5.3 Unbound free fatty acids 
Fatty acids are essential building blocks for many lipid molecules and are energy stores that 
can be utilized during times of fasting or increased metabolic demand. Fatty acids exist in 
body as esterified form (bound to glycerol or other alcohol), non-esterified form bound to 
albumin, and to a much smaller extent, as an unbound soluble form. Evidence exists that 
unbound free fatty acids increase significantly in ischemic-related events. It is not certain as 
of today what role the unbound free fatty acid plays in cardiac disease. It possibly partakes 
in the developing necrotic process and is released as a result of cell rupture or other 
precipitating conditions. Currently, a fluorescent probe assay is available but its clinical 
utility at this time is not established. 
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5.4 Fatty acid binding proteins (FABPs) 
Fatty acid binding proteins (FABPs) are transport proteins that carry fatty acids and other 
lipophilic molecules like eicosanoids and retinoids across the membranes. They occur in 
nine different isoforms in a predictable tissue distribution and fairly long half-life of several 
days. The heart-type FABP (H-FABP) is released following myocardial death within 6 hours 
and is not specific to the heart, similar to myoglobin. It is released to a smaller extent in 
skeletal muscle, distal tubular cells of the kidney, specific parts of the brain, lactating 
mammary glands, and the placenta.  It has been found that H-FABP may perform better and 
reach its upper reference limit sooner than either myoglobin or troponin. A number of 
enzyme immunoassays are available for H-FABP testing. Its relation to ischemia and 
prognosis for adverse events is likely to expound in near future. 
5.5 Phospholipase  
Phospholipase are the enzymes that release fatty acids from the second carbon group of 
glycerol. They are grouped into 4 major categories: A to D.  Phospholipase A2 and D have 
drawn much attention in their role in assessing ischemia associated coronary artery disease. 
Lipoprotein-associated phospholipase A2 (Lp-PLA2) also known as platelet-activating factor 
acetylhydrolase (PAF-AH) is a phospholipase A2 enzyme that in humans is encoded by 
the PLA2G7 gene. In human atherosclerotic lesions, 2 main sources of Lp-PLA2 can be 
identified, including that which is brought into the intima bound to LDL (from the 
circulation), and that which is synthesized de novo by plaque inflammatory cells 
(macrophages, T cells, mast cells). I A meta-analysis involving a total of 79,036 participants 
in 32 prospective studies found that Lp-PLA2 levels are positively correlated with increased 
risk of developing coronary heart disease and stroke. Recently, there has been a renewed 
interest in this molecule, not for use in cardiac assessment as it was originally approved by 
the FDA, but rather in stroke prediction after it was found that elevated levels of Lp-PLA2 
were associated with an almost 2-fold increase in stroke in the selected population coupled 
with a 6-fold increase in hypertensive individuals. 
Phospholipase D (PLD) is an enzyme that catalyzes the hydrolysis of membrane bound 
phospholipids into phosphatidic acid and choline. In addition, it is also involved in 
endorsement of fibrinogen binding to platelets. Increased levels of plasma (PLCHO) and 
whole blood choline (WBCHO) levels have been seen in tissue ischemia in patients with 
negative troponin values. Choline is not a marker for myocardial necrosis but indicated 
high-risk unstable angina in patients without acute myocardial infarction (sensitivity 86.4%, 
specificity 86.2%). Therefore obtaining levels of both plasma PLCHO and WBCHO may 
prove to be a useful aid in patients suspected of ACS. 
6. Conclusion 
Cardiac markers have been implicated in the diagnosis and risk stratification of patients 
with chest pain and suspected acute coronary syndrome (ACS). Among the markers of 
cardiac necrosis, troponins have become the cardiac markers of choice for patients with 
ACS. In fact, cardiac troponin has become central to the definition of acute myocardial 
infarction (MI) in the consensus guidelines from the American College of Cardiology (ACC) 
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and the European Society of Cardiology (ESC). Current focus is on finding appropriate 
upstream markers which may aid in detection of myocardial ischemia and a variety of 
events involved in the process of pathophysiology of acute coronary syndrome especially in 
relation to plaque destabilization and rupture. The ideal biomarkers that offer early 
detection, risk stratification, selection of therapy, monitoring disease progression, and 
treatment efficacy remain to be elucidated. 
7. References 
[1] Jaffe AS, Ravkilde J, Roberts R, et al. It's time for a change to a troponin standard. 
Circulation 2000; 102:1216. 
[2] Shave R, George KP, Atkinson G, et al. Exercise-induced cardiac troponin T release: a 
meta-analysis. Med Sci Sports Exerc 2007; 39:2099. 
[3] Gupta S, de Lemos JA. Use and misuse of cardiac troponins in clinical practice. Prog 
Cardiovasc Dis 2007; 50:151. 
[4] Müller-Bardorff M, Weidtmann B, Giannitsis E, et al. Release kinetics of cardiac 
troponin T in survivors of confirmed severe pulmonary embolism. Clin Chem 
2002; 48:673. 
[5] Carlson RJ, Navone A, McConnell JP, et al. Effect of myocardial ischemia on cardiac 
troponin I and T. Am J Cardiol 2002; 89:224. 
[6] Sabatine MS, Morrow DA, de Lemos JA, et al. Detection of acute changes in circulating 
troponin in the setting of transient stress test-induced myocardial ischaemia using 
an ultrasensitive assay: results from TIMI 35. Eur Heart J 2009; 30:162. 
[7] Kurz K, Giannitsis E, Zehelein J, Katus HA. Highly sensitive cardiac troponin T values 
remain constant after brief exercise- or pharmacologic-induced reversible 
myocardial ischemia. Clin Chem 2008; 54:1234. 
[8] Adams JE 3rd, Abendschein DR, Jaffe AS. Biochemical markers of myocardial injury. Is 
MB creatine kinase the choice for the 1990s? Circulation 1993; 88:750. 
[9] Katus HA, Remppis A, Scheffold T, et al. Intracellular compartmentation of cardiac 
troponin T and its release kinetics in patients with reperfused and nonreperfused 
myocardial infarction. Am J Cardiol 1991; 67:1360. 
[10] Adams JE 3rd, Schechtman KB, Landt Y, et al. Comparable detection of acute 
myocardial infarction by creatine kinase MB isoenzyme and cardiac troponin I. Clin 
Chem 1994; 40:1291. 
[11] Adams JE III, Bodor, GS, Davila-Roman, VG, et al. Cardiac troponin I. A marker with 
high specificity for cardiac injury. Circulation 1993; 88:101. 
[12] Bodor GS, Porterfield D, Voss EM, et al. Cardiac troponin-I is not expressed in fetal 
and healthy or diseased adult human skeletal muscle tissue. Clin Chem 1995; 
41:1710. 
[13] Ricchiuti V, Voss EM, Ney A, et al. Cardiac troponin T isoforms expressed in renal 
diseased skeletal muscle will not cause false-positive results by the second 
generation cardiac troponin T assay by Boehringer Mannheim. Clin Chem 1998; 
44:1919. 
[14] Panteghini M, Pagani F, Yeo KT, et al. Evaluation of imprecision for cardiac troponin 
assays at low-range concentrations. Clin Chem 2004; 50:327. 
www.intechopen.com
 
Cardiac Biomarkers 33 
[15] Apple FS, Quist HE, Doyle PJ, et al. Plasma 99th percentile reference limits for cardiac 
troponin and creatine kinase MB mass for use with European Society of 
Cardiology/American College of Cardiology consensus recommendations. Clin 
Chem 2003; 49:1331. 
[16] Shi Q, Ling M, Zhang X, et al. Degradation of cardiac troponin I in serum complicates 
comparisons of cardiac troponin I assays. Clin Chem 1999; 45:1018. 
[17] Labugger R, Organ L, Collier C, et al. Extensive troponin I and T modification detected 
in serum from patients with acute myocardial infarction. Circulation 2000; 
102:1221. 
[18] Heeschen C, Goldmann BU, Langenbrink L, et al. Evaluation of a rapid whole blood 
ELISA for quantification of troponin I in patients with acute chest pain. Clin Chem 
1999; 45:1789. 
[19] Katrukha AG, Bereznikova AV, Esakova TV, et al. Troponin I is released in bloodstream 
of patients with acute myocardial infarction not in free form but as complex. Clin 
Chem 1997; 43:1379. 
[20] Wu AH, Feng YJ, Moore R, et al. Characterization of cardiac troponin subunit release 
into serum after acute myocardial infarction and comparison of assays for troponin 
T and I. American Association for Clinical Chemistry Subcommittee on cTnI 
Standardization. Clin Chem 1998; 44:1198. 
[21] Thygesen K, Alpert JS, White HD, Joint ESC/ACCF/AHA/WHF Task Force for the 
Redefinition of Myocardial Infarction. Universal definition of myocardial 
infarction. Eur Heart J 2007; 28:2525. 
[22] Panteghini M, Gerhardt W, Apple FS, et al. Quality specifications for cardiac troponin 
assays. Clin Chem Lab Med 2001; 39:175. 
[23] Lee TH, Thomas EJ, Ludwig LE, et al. Troponin T as a marker for myocardial ischemia 
in patients undergoing major noncardiac surgery. Am J Cardiol 1996; 77:1031. 
[24] Baum H, Braun S, Gerhardt W, et al. Multicenter evaluation of a second-generation 
assay for cardiac troponin T. Clin Chem 1997; 43:1877. 
[25] Apple FS, Parvin CA, Buechler KF, et al. Validation of the 99th percentile cutoff 
independent of assay imprecision (CV) for cardiac troponin monitoring for ruling 
out myocardial infarction. Clin Chem 2005; 51:2198. 
[26] Wu AH, Jaffe AS. The clinical need for high-sensitivity cardiac troponin assays for acute 
coronary syndromes and the role for serial testing. Am Heart J 2008; 155:208. 
[27] Zethelius B, Johnston N, Venge P. Troponin I as a predictor of coronary heart disease 
and mortality in 70-year-old men: a community-based cohort study. Circulation 
2006; 113:1071. 
[28] Kavsak PA, Newman AM, Lustig V, et al. Long-term health outcomes associated with 
detectable troponin I concentrations. Clin Chem 2007; 53:220. 
[29] Waxman DA, Hecht S, Schappert J, Husk G. A model for troponin I as a quantitative 
predictor of in-hospital mortality. J Am Coll Cardiol 2006; 48:1755. 
[30] Schulz O, Kirpal K, Stein J, et al. Importance of low concentrations of cardiac troponins. 
Clin Chem 2006; 52:1614. 
www.intechopen.com
 
Novel Strategies in Ischemic Heart Disease 34
[31] Wu AH, Fukushima N, Puskas R, et al. Development and preliminary clinical 
validation of a high sensitivity assay for cardiac troponin using a capillary flow 
(single molecule) fluorescence detector. Clin Chem 2006; 52:2157. 
[32] Kavsak PA, MacRae AR, Yerna MJ, Jaffe AS. Analytic and clinical utility of a next-
generation, highly sensitive cardiac troponin I assay for early detection of 
myocardial injury. Clin Chem 2009; 55:573. 
[33] Wilson SR, Sabatine MS, Braunwald E, et al. Detection of myocardial injury in patients 
with unstable angina using a novel nanoparticle cardiac troponin I assay: 
observations from the PROTECT-TIMI 30 Trial. Am Heart J 2009; 158:386. 
[34] Venge P, Johnston N, Lindahl B, James S. Normal plasma levels of cardiac troponin I 
measured by the high-sensitivity cardiac troponin I access prototype assay and 
the impact on the diagnosis of myocardial ischemia. J Am Coll Cardiol 2009; 
54:1165. 
[35] Giannitsis E, Kurz K, Hallermayer K, et al. Analytical validation of a high-sensitivity 
cardiac troponin T assay. Clin Chem 2010; 56:254. 
[36] Latini R, Masson S, Anand IS, et al. Prognostic value of very low plasma concentrations 
of troponin T in patients with stable chronic heart failure. Circulation 2007; 
116:1242. 
[37] Januzzi JL Jr, Bamberg F, Lee H, et al. High-sensitivity troponin T concentrations in 
acute chest pain patients evaluated with cardiac computed tomography. 
Circulation 2010; 121:1227. 
[38] Diamond GA, Kaul S. How would the Reverend Bayes interpret high-sensitivity 
troponin? Circulation 2010; 121:1172. 
[39] Kavsak PA, Wang X, Ko DT, et al. Short- and long-term risk stratification using a next-
generation, high-sensitivity research cardiac troponin I (hs-cTnI) assay in an 
emergency department chest pain population. Clin Chem 2009; 55:1809. 
[40] Derdeyn CP. Moyamoya disease and moyamoya syndrome. N Engl J Med 2009; 361:97; 
author reply 98. 
[41] de Lemos JA, Drazner MH, Omland T, et al. Association of troponin T detected with a 
highly sensitive assay and cardiac structure and mortality risk in the general 
population. JAMA 2010; 304:2503. 
[42] deFilippi CR, de Lemos JA, Christenson RH, et al. Association of serial measures of 
cardiac troponin T using a sensitive assay with incident heart failure and 
cardiovascular mortality in older adults. JAMA 2010; 304:2494. 
[43] Katus HA, Giannitsis E, Jaffe AS, Thygesen K. Higher sensitivity troponin assays: Quo 
vadis? Eur Heart J 2009; 30:127. 
[44] Wallace TW, Abdullah SM, Drazner MH, et al. Prevalence and determinants of troponin 
T elevation in the general population. Circulation 2006; 113:1958. 
[45] Daniels LB, Laughlin GA, Clopton P, et al. Minimally elevated cardiac troponin T and 
elevated N-terminal pro-B-type natriuretic peptide predict mortality in older 
adults: results from the Rancho Bernardo Study. J Am Coll Cardiol 2008; 52:450. 
[46] Jaffe AS. Chasing troponin: how low can you go if you can see the rise? J Am Coll 
Cardiol 2006; 48:1763. 
www.intechopen.com
 
Cardiac Biomarkers 35 
[47] Mills NL, Churchhouse AM, Lee KK, et al. Implementation of a sensitive troponin I 
assay and risk of recurrent myocardial infarction and death in patients with 
suspected acute coronary syndrome. JAMA 2011; 305:1210. 
[48] Saenger AK, Jaffe AS. Requiem for a heavyweight: the demise of creatine kinase-MB. 
Circulation 2008; 118:2200. 
[49] Antman, EM, Anbe, DT, Armstrong, PW, et al. ACC/AHA guidelines for the 
management of patients with ST-elevation myocardial infarction. 
www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 
2006). 
[50] Macrae AR, Kavsak PA, Lustig V, et al. Assessing the requirement for the 6-hour 
interval between specimens in the American Heart Association Classification of 
Myocardial Infarction in Epidemiology and Clinical Research Studies. Clin Chem 
2006; 52:812. 
[51] Eggers KM, Oldgren J, Nordenskjöld A, Lindahl B. Diagnostic value of serial 
measurement of cardiac markers in patients with chest pain: limited value of 
adding myoglobin to troponin I for exclusion of myocardial infarction. Am Heart J 
2004; 148:574. 
[52] Hollander JE, Levitt MA, Young GP, et al. Effect of recent cocaine use on the specificity 
of cardiac markers for diagnosis of acute myocardial infarction. Am Heart J 1998; 
135:245. 
[53] Reichlin T, Hochholzer W, Bassetti S, et al. Early diagnosis of myocardial infarction 
with sensitive cardiac troponin assays. N Engl J Med 2009; 361:858. 
[54] Keller T, Zeller T, Peetz D, et al. Sensitive troponin I assay in early diagnosis of acute 
myocardial infarction. N Engl J Med 2009; 361:868. 
[55] Jaffe, AS and Apple FS. High-sensitivity cardiac troponin: Hype, help, and reality. 
Clinical chemistry 2009; Dec 30. [E pub ahead of print]. 
[56] Antman, EM, Hand, M, Armstrong, PW, et al. 2007 focused update of the ACC/AHA 
2004 Guidelines for the Management of Patients With ST-Elevation Myocardial 
Infarction: a report of the American College of Cardiology/American Heart 
Association Task Force on Practice Guidelines (Writing Group to Review New 
Evidence and Update the ACC/AHA 2004 Guidelines for the Management of 
Patients With ST-Elevation Myocardial Infarction). J Am Coll Cardiol 2008; 51:XXX. 
Available at: www.acc.org/qualityandscience/clinical/statements.htm (accessed 
September 18, 2007). 
[57] deFilippi CR, Tocchi M, Parmar RJ, et al. Cardiac troponin T in chest pain unit patients 
without ischemic electrocardiographic changes: angiographic correlates and long-
term clinical outcomes. J Am Coll Cardiol 2000; 35:1827. 
[58] Ohman EM, Christenson RH, Califf RM, et al. Noninvasive detection of reperfusion 
after thrombolysis based on serum creatine kinase MB changes and clinical 
variables. TAMI 7 Study Group. Thrombolysis and Angioplasty in Myocardial 
Infarction. Am Heart J 1993; 126:819. 
[59] Christenson RH, Ohman EM, Topol EJ, et al. Assessment of coronary reperfusion after 
thrombolysis with a model combining myoglobin, creatine kinase-MB, and clinical 
www.intechopen.com
 
Novel Strategies in Ischemic Heart Disease 36
variables. TAMI-7 Study Group. Thrombolysis and Angioplasty in Myocardial 
Infarction-7. Circulation 1997; 96:1776. 
[60] Apple FS, Murakami MM. Cardiac troponin and creatine kinase MB monitoring during 
in-hospital myocardial reinfarction. Clin Chem 2005; 51:460. 
[61] Babuin L, Vasile VC, Rio Perez JA, et al. Elevated cardiac troponin is an independent 
risk factor for short- and long-term mortality in medical intensive care unit 
patients. Crit Care Med 2008; 36:759. 
[62] Allan JJ, Feld RD, Russell AA, et al. Cardiac troponin I levels are normal or minimally 
elevated after transthoracic cardioversion. J Am Coll Cardiol 1997; 30:1052. 
[63] Licka M, Zimmermann R, Zehelein J, et al. Troponin T concentrations 72 hours after 
myocardial infarction as a serological estimate of infarct size. Heart 2002; 87:520. 
[64] Panteghini M, Cuccia C, Bonetti G, et al. Single-point cardiac troponin T at coronary 
care unit discharge after myocardial infarction correlates with infarct size and 
ejection fraction. Clin Chem 2002; 48:1432. 
[65] Steen H, Giannitsis E, Futterer S, et al. Cardiac troponin T at 96 hours after acute 
myocardial infarction correlates with infarct size and cardiac function. J Am Coll 
Cardiol 2006; 48:2192. 
[66] Giannitsis E, Steen H, Kurz K, et al. Cardiac magnetic resonance imaging study for 
quantification of infarct size comparing directly serial versus single time-point 
measurements of cardiac troponin T. J Am Coll Cardiol 2008; 51:307. 
[67] Vasile VC, Babuin L, Giannitsis E, et al. Relationship of MRI-determined infarct size and 
cTnI measurements in patients with ST-elevation myocardial infarction. Clin Chem 
2008; 54:617. 
[68] Olatidoye AG, Wu AH, Feng YJ, Waters D. Prognostic role of troponin T versus 
troponin I in unstable angina pectoris for cardiac events with meta-analysis 
comparing published studies. Am J Cardiol 1998; 81:1405. 
[69] Heidenreich PA, Alloggiamento T, Melsop K, et al. The prognostic value of troponin in 
patients with non-ST elevation acute coronary syndromes: a meta-analysis. J Am 
Coll Cardiol 2001; 38:478. 
[70] Heeschen C, Hamm CW, Goldmann B, et al. Troponin concentrations for stratification 
of patients with acute coronary syndromes in relation to therapeutic efficacy of 
tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic 
Syndrome Management. Lancet 1999; 354:1757. 
[71] James S, Armstrong P, Califf R, et al. Troponin T levels and risk of 30-day outcomes in 
patients with the acute coronary syndrome: prospective verification in the GUSTO-
IV trial. Am J Med 2003; 115:178. 
[72] Ohman EM, Armstrong PW, White HD, et al. Risk stratification with a point-of-care 
cardiac troponin T test in acute myocardial infarction. GUSTOIII Investigators. 
Global Use of Strategies To Open Occluded Coronary Arteries. Am J Cardiol 1999; 
84:1281. 
[73] Giannitsis E, Müller-Bardorff M, Lehrke S, et al. Admission troponin T level predicts 
clinical outcomes, TIMI flow, and myocardial tissue perfusion after primary 
percutaneous intervention for acute ST-segment elevation myocardial infarction. 
Circulation 2001; 104:630. 
www.intechopen.com
 
Cardiac Biomarkers 37 
[74] Ottani F, Galvani M, Nicolini FA, et al. Elevated cardiac troponin levels predict the risk 
of adverse outcome in patients with acute coronary syndromes. Am Heart J 2000; 
140:917. 
[75] Morrow DA, Antman EM, Tanasijevic M, et al. Cardiac troponin I for stratification of 
early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B 
substudy. J Am Coll Cardiol 2000; 36:1812. 
[76] Lindahl B, Venge P, Wallentin L. Relation between troponin T and the risk of 
subsequent cardiac events in unstable coronary artery disease. The FRISC study 
group. Circulation 1996; 93:1651. 
[77] Antman EM, Tanasijevic MJ, Thompson B, et al. Cardiac-specific troponin I levels to 
predict the risk of mortality in patients with acute coronary syndromes. N Engl J 
Med 1996; 335:1342. 
[78] Ohman EM, Armstrong PW, Christenson RH, et al. Cardiac troponin T levels for risk 
stratification in acute myocardial ischemia. GUSTO IIA Investigators. N Engl J Med 
1996; 335:1333. 
[79] Hamm CW, Goldmann BU, Heeschen C, et al. Emergency room triage of patients with 
acute chest pain by means of rapid testing for cardiac troponin T or troponin I. N 
Engl J Med 1997; 337:1648. 
[80] Lindahl B, Diderholm E, Lagerqvist B, et al. Mechanisms behind the prognostic value of 
troponin T in unstable coronary artery disease: a FRISC II substudy. J Am Coll 
Cardiol 2001; 38:979. 
[81] Heeschen C, Hamm CW, Bruemmer J, Simoons ML. Predictive value of C-reactive 
protein and troponin T in patients with unstable angina: a comparative analysis. 
CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina 
REfractory to standard treatment trial. J Am Coll Cardiol 2000; 35:1535. 
[82] Lindahl B, Toss H, Siegbahn A, et al. Markers of myocardial damage and inflammation 
in relation to long-term mortality in unstable coronary artery disease. FRISC Study 
Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med 2000; 
343:1139. 
[83] Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-
ST elevation MI: A method for prognostication and therapeutic decision making. 
JAMA 2000; 284:835. 
[84] Morrow DA, Cannon CP, Rifai N, et al. Ability of minor elevations of troponins I and T 
to predict benefit from an early invasive strategy in patients with unstable angina 
and non-ST elevation myocardial infarction: results from a randomized trial. JAMA 
2001; 286:2405. 
[85] Kleiman NS, Lakkis N, Cannon CP, et al. Prospective analysis of creatine kinase muscle-
brain fraction and comparison with troponin T to predict cardiac risk and benefit of 
an invasive strategy in patients with non-ST-elevation acute coronary syndromes. J 
Am Coll Cardiol 2002; 40:1044. 
[86] Diderholm E, Andrén B, Frostfeldt G, et al. The prognostic and therapeutic implications 
of increased troponin T levels and ST depression in unstable coronary artery 
disease: the FRISC II invasive troponin T electrocardiogram substudy. Am Heart J 
2002; 143:760. 
www.intechopen.com
 
Novel Strategies in Ischemic Heart Disease 38
[87] Heeschen C, van Den Brand MJ, Hamm CW, Simoons ML. Angiographic findings in 
patients with refractory unstable angina according to troponin T status. Circulation 
1999; 100:1509. 
[88] Martinez MW, Babuin L, Syed IS, et al. Myocardial infarction with normal coronary 
arteries: a role for MRI? Clin Chem 2007; 53:995. 
[89] Christiansen JP, Edwards C, Sinclair T, et al. Detection of myocardial scar by contrast-
enhanced cardiac magnetic resonance imaging in patients with troponin-positive 
chest pain and minimal angiographic coronary artery disease. Am J Cardiol 2006; 
97:768. 
[90] Dokainish H, Pillai M, Murphy SA, et al. Prognostic implications of elevated troponin in 
patients with suspected acute coronary syndrome but no critical epicardial 
coronary disease: a TACTICS-TIMI-18 substudy. J Am Coll Cardiol 2005; 45:19. 
[91] James SK, Armstrong P, Barnathan E, et al. Troponin and C-reactive protein have 
different relations to subsequent mortality and myocardial infarction after acute 
coronary syndrome: a GUSTO-IV substudy. J Am Coll Cardiol 2003; 41:916. 
[92] Kontos MC, Shah R, Fritz LM, et al. Implication of different cardiac troponin I levels for 
clinical outcomes and prognosis of acute chest pain patients. J Am Coll Cardiol 
2004; 43:958. 
[93] Mueller C, Neumann FJ, Perruchoud AP, et al. Prognostic value of quantitative 
troponin T measurements in unstable angina/non-ST-segment elevation acute 
myocardial infarction treated early and predominantly with percutaneous coronary 
intervention. Am J Med 2004; 117:897. 
[94] Newby LK, Christenson RH, Ohman EM, et al. Value of serial troponin T measures for 
early and late risk stratification in patients with acute coronary syndromes. The 
GUSTO-IIa Investigators. Circulation 1998; 98:1853. 
[95] Antman EM. Troponin measurements in ischemic heart disease: more than just a black 
and white picture. J Am Coll Cardiol 2001; 38:987. 
[96] Bessman SP, Carpenter CL. The creatine-creatine phosphate energy shuttle. Annu Rev 
Biochem 1985; 54:831. 
[97] Roberts R, Gowda KS, Ludbrook PA, Sobel BE. Specificity of elevated serum MB 
creatine phosphokinase activity in the diagnosis of acute myocardial infarction. Am 
J Cardiol 1975; 36:433. 
[98] Tsung JS, Tsung SS. Creatine kinase isoenzymes in extracts of various human skeletal 
muscles. Clin Chem 1986; 32:1568. 
[99] Neumeier, D. Tissue specific and subcellular distribution of creatine kinase isoenzymes. 
In: Creatine Kinase Isoenzymes, Lang, H (Ed), Springer-Verlag, Berlin/Heidelberg 
1981. p.85. 
[100] Trask RV, Billadello JJ. Tissue-specific distribution and developmental regulation of M 
and B creatine kinase mRNAs. Biochim Biophys Acta 1990; 1049:182. 
[101] Fontanet HL, Trask RV, Haas RC, et al. Regulation of expression of M, B, and 
mitochondrial creatine kinase mRNAs in the left ventricle after pressure overload 
in rats. Circ Res 1991; 68:1007. 
[102] Wolf PL. Abnormalities in serum enzymes in skeletal muscle diseases. Am J Clin 
Pathol 1991; 95:293. 
www.intechopen.com
 
Cardiac Biomarkers 39 
[103] Siegel AJ, Silverman LM, Evans WJ. Elevated skeletal muscle creatine kinase MB 
isoenzyme levels in marathon runners. JAMA 1983; 250:2835. 
[104] Clark GL, Robison AK, Gnepp DR, et al. Effects of lymphatic transport of enzyme on 
plasma creatine kinase time-activity curves after myocardial infarction in dogs. Circ 
Res 1978; 43:162. 
[105] Vatner SF, Baig H, Manders WT, Maroko PR. Effects of coronary artery reperfusion 
on myocardial infarct size calculated from creatine kinase. J Clin Invest 1978; 
61:1048. 
[106] Dillon MC, Calbreath DF, Dixon AM, et al. Diagnostic problem in acute myocardial 
infarction: CK-MB in the absence of abnormally elevated total creatine kinase 
levels. Arch Intern Med 1982; 142:33. 
[107] Heller GV, Blaustein AS, Wei JY. Implications of increased myocardial isoenzyme 
level in the presence of normal serum creatine kinase activity. Am J Cardiol 1983; 
51:24. 
[108] Yusuf S, Collins R, Lin L, et al. Significance of elevated MB isoenzyme with normal 
creatine kinase in acute myocardial infarction. Am J Cardiol 1987; 59:245. 
[109] Puleo PR, Guadagno PA, Roberts R, et al. Early diagnosis of acute myocardial 
infarction based on assay for subforms of creatine kinase-MB. Circulation 1990; 
82:759. 
[110] Puleo PR, Meyer D, Wathen C, et al. Use of a rapid assay of subforms of creatine 
kinase-MB to diagnose or rule out acute myocardial infarction. N Engl J Med 1994; 
331:561. 
[111] Jaffe AS, Landt Y, Parvin CA, et al. Comparative sensitivity of cardiac troponin I and 
lactate dehydrogenase isoenzymes for diagnosing acute myocardial infarction. Clin 
Chem 1996; 42:1770. 
[112] Adams JE 3rd, Dávila-Román VG, Bessey PQ, et al. Improved detection of cardiac 
contusion with cardiac troponin I. Am Heart J 1996; 131:308. 
[113] Adams JE 3rd, Sicard GA, Allen BT, et al. Diagnosis of perioperative myocardial 
infarction with measurement of cardiac troponin I. N Engl J Med 1994; 330:670. 
[114] Larca LJ, Coppola JT, Honig S. Creatine kinase MB isoenzyme in dermatomyositis: a 
noncardiac source. Ann Intern Med 1981; 94:341. 
[115] Lenke LG, Bridwell KH, Jaffe AS. Increase in creatine kinase MB isoenzyme levels after 
spinal surgery. J Spinal Disord 1994; 7:70. 
[116] Badsha H, Gunes B, Grossman J, Brahn E. Troponin I Assessment of Cardiac 
Involvement in Patients With Connective Tissue Disease and an Elevated Creatine 
Kinase MB Isoform Report of Four Cases and Review of the Literature. J Clin 
Rheumatol 1997; 3:131. 
[117] Hochberg MC, Koppes GM, Edwards CQ, et al. Hypothyroidism presenting as a 
polymyositis-like syndrome. Report of two cases. Arthritis Rheum 1976; 19:1363. 
[118] Jaffe AS, Ritter C, Meltzer V, et al. Unmasking artifactual increases in creatine kinase 
isoenzymes in patients with renal failure. J Lab Clin Med 1984; 104:193. 
[119] Gutovitz AL, Sobel BE, Roberts R. Progressive nature of myocardial injury in selected 
patients with cardiogenic shock. Am J Cardiol 1978; 41:469. 
www.intechopen.com
 
Novel Strategies in Ischemic Heart Disease 40
[120] Alexander JH, Sparapani RA, Mahaffey KW, et al. Association between minor 
elevations of creatine kinase-MB level and mortality in patients with acute coronary 
syndromes without ST-segment elevation. PURSUIT Steering Committee. Platelet 
Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin 
Therapy. JAMA 2000; 283:347. 
[121] Savonitto S, Granger CB, Ardissino D, et al. The prognostic value of creatine kinase 
elevations extends across the whole spectrum of acute coronary syndromes. J Am 
Coll Cardiol 2002; 39:22. 
[122] Halkin A, Stone GW, Grines CL, et al. Prognostic implications of creatine kinase 
elevation after primary percutaneous coronary intervention for acute myocardial 
infarction. J Am Coll Cardiol 2006; 47:951. 
[123] Galla JM, Mahaffey KW, Sapp SK, et al. Elevated creatine kinase-MB with normal 
creatine kinase predicts worse outcomes in patients with acute coronary 
syndromes: results from 4 large clinical trials. Am Heart J 2006; 151:16. 
[124] Lloyd-Jones DM, Camargo CA Jr, Giugliano RP, et al. Characteristics and prognosis of 
patients with suspected acute myocardial infarction and elevated MB relative index 
but normal total creatine kinase. Am J Cardiol 1999; 84:957. 
[125] Newby LK, Roe MT, Chen AY, et al. Frequency and clinical implications of discordant 
creatine kinase-MB and troponin measurements in acute coronary syndromes. J 
Am Coll Cardiol 2006; 47:312. 
[126] Rao SV, Ohman EM, Granger CB, et al. Prognostic value of isolated troponin elevation 
across the spectrum of chest pain syndromes. Am J Cardiol 2003; 91:936. 
[127] Goodman SG, Steg PG, Eagle KA, et al. The diagnostic and prognostic impact of the 
redefinition of acute myocardial infarction: lessons from the Global Registry of 
Acute Coronary Events (GRACE). Am Heart J 2006; 151:654. 
[128] Califf RM, Abdelmeguid AE, Kuntz RE, et al. Myonecrosis after revascularization 
procedures. J Am Coll Cardiol 1998; 31:241. 
[129] Tardiff BE, Califf RM, Tcheng JE, et al. Clinical outcomes after detection of elevated 
cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II 
Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and 
Coronary Thrombosis-II. J Am Coll Cardiol 1999; 33:88. 
[130] Simoons ML, van den Brand M, Lincoff M, et al. Minimal myocardial damage during 
coronary intervention is associated with impaired outcome. Eur Heart J 1999; 
20:1112. 
[131] Cavallini C, Savonitto S, Violini R, et al. Impact of the elevation of biochemical 
markers of myocardial damage on long-term mortality after percutaneous 
coronary intervention: results of the CK-MB and PCI study. Eur Heart J 2005; 
26:1494. 
[132] Cantor WJ, Newby LK, Christenson RH, et al. Prognostic significance of elevated 
troponin I after percutaneous coronary intervention. J Am Coll Cardiol 2002; 
39:1738. 
[133] Kizer JR, Muttrej MR, Matthai WH, et al. Role of cardiac troponin T in the long-term 
risk stratification of patients undergoing percutaneous coronary intervention. Eur 
Heart J 2003; 24:1314. 
www.intechopen.com
 
Cardiac Biomarkers 41 
[134] Nageh T, Sherwood RA, Harris BM, et al. Cardiac troponin T and I and creatine 
kinase-MB as markers of myocardial injury and predictors of outcome following 
percutaneous coronary intervention. Int J Cardiol 2003; 92:285. 
[135] Kini AS, Lee P, Marmur JD, et al. Correlation of postpercutaneous coronary 
intervention creatine kinase-MB and troponin I elevation in predicting mid-term 
mortality. Am J Cardiol 2004; 93:18. 
[136] Wu AH, Boden WE, McKay RG. Long-term follow-up of patients with increased 
cardiac troponin concentrations following percutaneous coronary intervention. Am 
J Cardiol 2002; 89:1300. 
[137] Miller WL, Garratt KN, Burritt MF, et al. Baseline troponin level: key to 
understanding the importance of post-PCI troponin elevations. Eur Heart J 2006; 
27:1061. 
[138] Prasad A, Rihal CS, Lennon RJ, et al. Significance of periprocedural myonecrosis on 
outcomes following Percutaneous coronary intervention. Circ Cardiovasc Intervent 
2008; 1:9. 
[139] Pierpont GL, McFalls EO. Interpreting troponin elevations: do we need multiple 
diagnoses? Eur Heart J 2009; 30:135. 
[140] Prasad A, Singh M, Lerman A, et al. Isolated elevation in troponin T after 
percutaneous coronary intervention is associated with higher long-term mortality. J 
Am Coll Cardiol 2006; 48:1765. 
[141] Nienhuis MB, Ottervanger JP, Dikkeschei B, et al. Prognostic importance of troponin T 
and creatine kinase after elective angioplasty. Int J Cardiol 2007; 120:242. 
[142] Kleiman NS. Measuring troponin elevation after percutaneous coronary intervention: 
ready for prime time? J Am Coll Cardiol 2006; 48:1771. 
[143] Costa MA, Carere RG, Lichtenstein SV, et al. Incidence, predictors, and significance of 
abnormal cardiac enzyme rise in patients treated with bypass surgery in the arterial 
revascularization therapies study (ARTS). Circulation 2001; 104:2689. 
[144] Brener SJ, Lytle BW, Schneider JP, et al. Association between CK-MB elevation after 
percutaneous or surgical revascularization and three-year mortality. J Am Coll 
Cardiol 2002; 40:1961. 
[145] Januzzi JL, Lewandrowski K, MacGillivray TE, et al. A comparison of cardiac troponin 
T and creatine kinase-MB for patient evaluation after cardiac surgery. J Am Coll 
Cardiol 2002; 39:1518. 
[146] Steuer J, Bjerner T, Duvernoy O, et al. Visualisation and quantification of peri-
operative myocardial infarction after coronary artery bypass surgery with contrast-
enhanced magnetic resonance imaging. Eur Heart J 2004; 25:1293. 
[147] Carrier M, Pellerin M, Perrault LP, et al. Troponin levels in patients with myocardial 
infarction after coronary artery bypass grafting. Ann Thorac Surg 2000; 69:435. 
[148] Croal BL, Hillis GS, Gibson PH, et al. Relationship between postoperative cardiac 
troponin I levels and outcome of cardiac surgery. Circulation 2006; 114:1468. 
[149] Thielmann M, Massoudy P, Jaeger BR, et al. Emergency re-revascularization with 
percutaneous coronary intervention, reoperation, or conservative treatment in 
patients with acute perioperative graft failure following coronary artery bypass 
surgery. Eur J Cardiothorac Surg 2006; 30:117. 
www.intechopen.com
 
Novel Strategies in Ischemic Heart Disease 42
[150] Morrow DA, Cannon CP, Jesse RL, et al. National Academy of Clinical Biochemistry 
Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of 
biochemical markers in acute coronary syndromes. Clin Chem 2007; 53:552. 
www.intechopen.com
Novel Strategies in Ischemic Heart Disease
Edited by Dr. Umashankar Lakshmanadoss
ISBN 978-953-51-0184-0
Hard cover, 450 pages
Publisher InTech
Published online 29, February, 2012
Published in print edition February, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
The first edition of this book will provide a comprehensive overview of ischemic heart disease, including
epidemiology, risk factors, pathogenesis, clinical presentation, diagnostic tests, differential diagnosis,
treatment, complications and prognosis. Also discussed are current treatment options, protocols and
diagnostic procedures, as well as the latest advances in the field. The book will serve as a cutting-edge point
of reference for the basic or clinical researcher, and any clinician involved in the diagnosis and management of
ischemic heart disease. This book is essentially designed to fill the vital gap existing between these practices,
to provide a textbook that is substantial and readable, compact and reasonably comprehensive, and to provide
an excellent blend of "basics to bedside and beyond" in the field of ischemic heart disease. The book also
covers the future novel treatment strategies, focusing on the basic scientific and clinical aspects of the
diagnosis and management of ischemic heart disease.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Sadip Pant, Abhishek Deshmukh, Pritam Neupane, M.P. Kavin Kumar and C.S. Vijayashankar (2012). Cardiac
Biomarkers, Novel Strategies in Ischemic Heart Disease, Dr. Umashankar Lakshmanadoss (Ed.), ISBN: 978-
953-51-0184-0, InTech, Available from: http://www.intechopen.com/books/novel-strategies-in-ischemic-heart-
disease/biomarkers-in-ischemic-heart-disease
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
